192 related articles for article (PubMed ID: 28669127)
1. Ensemble-based virtual screening: identification of a potential allosteric inhibitor of Bcr-Abl.
Singh VK; Coumar MS
J Mol Model; 2017 Jul; 23(7):218. PubMed ID: 28669127
[TBL] [Abstract][Full Text] [Related]
2. Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors.
Singh VK; Chang HH; Kuo CC; Shiao HY; Hsieh HP; Coumar MS
J Biomol Struct Dyn; 2017 Jun; 35(8):1833-1848. PubMed ID: 27353341
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study.
Banavath HN; Sharma OP; Kumar MS; Baskaran R
Sci Rep; 2014 Nov; 4():6948. PubMed ID: 25382104
[TBL] [Abstract][Full Text] [Related]
4. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
Kumar H; Raj U; Gupta S; Varadwaj PK
J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
[TBL] [Abstract][Full Text] [Related]
5. Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance.
El Rashedy AA; Olotu FA; Soliman MES
Chem Biodivers; 2018 Mar; 15(3):e1700533. PubMed ID: 29325229
[TBL] [Abstract][Full Text] [Related]
6. Insight into the allosteric inhibition of Abl kinase.
Fallacara AL; Tintori C; Radi M; Schenone S; Botta M
J Chem Inf Model; 2014 May; 54(5):1325-38. PubMed ID: 24787133
[TBL] [Abstract][Full Text] [Related]
7. Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate.
Gray NS; Fabbro D
Methods Enzymol; 2014; 548():173-88. PubMed ID: 25399646
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 2-Acylaminothiophene-3-Carboxamides as Multitarget Inhibitors for BCR-ABL Kinase and Microtubules.
Cao R; Wang Y; Huang N
J Chem Inf Model; 2015 Nov; 55(11):2435-42. PubMed ID: 26501568
[TBL] [Abstract][Full Text] [Related]
9. Computational dissection of allosteric inhibition of the SH2 domain of Bcr-Abl kinase by the monobody inhibitor AS25.
Ji M; Zheng G; Li X; Zhang Z; Jv G; Wang X; Wang J
J Mol Model; 2017 Jun; 23(6):183. PubMed ID: 28488190
[TBL] [Abstract][Full Text] [Related]
10. Identification of natural inhibitors of Bcr-Abl for the treatment of chronic myeloid leukemia.
Parcha P; Sarvagalla S; Madhuri B; Pajaniradje S; Baskaran V; Coumar MS; Rajasekaran B
Chem Biol Drug Des; 2017 Oct; 90(4):596-608. PubMed ID: 28338290
[TBL] [Abstract][Full Text] [Related]
11. In silico drug repurposing of FDA-approved drugs to predict new inhibitors for drug resistant T315I mutant and wild-type BCR-ABL1: A virtual screening and molecular dynamics study.
Sohraby F; Bagheri M; Aliyar M; Aryapour H
J Mol Graph Model; 2017 Jun; 74():234-240. PubMed ID: 28458002
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel Bcr-Abl inhibitors targeting myristoyl pocket and ATP site.
Dong J; Lu W; Pan X; Su P; Shi Y; Wang J; Zhang J
Bioorg Med Chem; 2014 Dec; 22(24):6876-84. PubMed ID: 25464886
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.
Fabbro D; Manley PW; Jahnke W; Liebetanz J; Szyttenholm A; Fendrich G; Strauss A; Zhang J; Gray NS; Adrian F; Warmuth M; Pelle X; Grotzfeld R; Berst F; Marzinzik A; Cowan-Jacob SW; Furet P; Mestan J
Biochim Biophys Acta; 2010 Mar; 1804(3):454-62. PubMed ID: 20152788
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.
von Bubnoff N; Veach DR; Miller WT; Li W; Sänger J; Peschel C; Bornmann WG; Clarkson B; Duyster J
Cancer Res; 2003 Oct; 63(19):6395-404. PubMed ID: 14559829
[TBL] [Abstract][Full Text] [Related]
15. Expanding the diversity of allosteric bcr-abl inhibitors.
Deng X; Okram B; Ding Q; Zhang J; Choi Y; Adrián FJ; Wojciechowski A; Zhang G; Che J; Bursulaya B; Cowan-Jacob SW; Rummel G; Sim T; Gray NS
J Med Chem; 2010 Oct; 53(19):6934-46. PubMed ID: 20828158
[TBL] [Abstract][Full Text] [Related]
16. Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to.
Carofiglio F; Trisciuzzi D; Gambacorta N; Leonetti F; Stefanachi A; Nicolotti O
Molecules; 2020 Sep; 25(18):. PubMed ID: 32937901
[TBL] [Abstract][Full Text] [Related]
17. Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Adrián FJ; Ding Q; Sim T; Velentza A; Sloan C; Liu Y; Zhang G; Hur W; Ding S; Manley P; Mestan J; Fabbro D; Gray NS
Nat Chem Biol; 2006 Feb; 2(2):95-102. PubMed ID: 16415863
[TBL] [Abstract][Full Text] [Related]
18. NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors.
Skora L; Mestan J; Fabbro D; Jahnke W; Grzesiek S
Proc Natl Acad Sci U S A; 2013 Nov; 110(47):E4437-45. PubMed ID: 24191057
[TBL] [Abstract][Full Text] [Related]
19. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
20. A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant.
Radi M; Schneider R; Fallacara AL; Botta L; Crespan E; Tintori C; Maga G; Kissova M; Calgani A; Richters A; Musumeci F; Rauh D; Schenone S
Bioorg Med Chem Lett; 2016 Aug; 26(15):3436-40. PubMed ID: 27374241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
